Education
About Us
Working with TipRanks
Follow Us
Onconetix (ONCO)
NASDAQ:ONCO
ONCO Stock Chart & Stats
$0.67
-$0.03(-5.61%)
At close: 4:00 PM EST
$0.67
-$0.03(-5.61%)
Day’s Range― - ―
52-Week Range$0.62 - $20.83
Previous CloseN/A
Volume794.62K
Average Volume (3M)207.81K
Market Cap
$1.05M
Enterprise Value-$285.03K
Total Cash (Recent Filing)$836.56K
Total Debt (Recent Filing)$166.42K
Price to Earnings (P/E)―
Beta2.58
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-88.84
Shares Outstanding1,555,015
10 Day Avg. Volume109,373
30 Day Avg. Volume207,813
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.18
Price to Sales (P/S)0.69
P/FCF Ratio-0.16
Enterprise Value/Market Cap-0.27
Enterprise Value/Revenue-0.23
Enterprise Value/Gross Profit-0.27
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4,012
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Innovative Product PortfolioOnconetix's focus on advanced cancer diagnostics and personalized therapeutics positions it well in the biotech industry, leveraging technology for improved patient outcomes.
Strategic PartnershipsCollaborations with larger firms can enhance product development and market reach, providing shared revenue opportunities and access to broader resources.
Revenue Growth PotentialLicensing proprietary technologies to other firms offers a scalable revenue stream, potentially increasing market penetration and financial stability over time.
Bears Say
Negative Profit MarginsPersistent negative profit margins indicate ongoing financial challenges, potentially limiting reinvestment capabilities and affecting long-term viability.
Strained Cash FlowsNegative operating cash flow suggests difficulties in covering operational expenses, which can hinder growth initiatives and necessitate external financing.
High Operating LossesSignificant operating losses reflect inefficiencies and financial strain, challenging the company's ability to achieve profitability and necessitating cost management.
Onconetix News
ONCO FAQ
What was Onconetix’s price range in the past 12 months?
Onconetix lowest stock price was $0.62 and its highest was $20.82 in the past 12 months.
What is Onconetix’s market cap?
Onconetix’s market cap is $1.05M.
When is Onconetix’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Onconetix’s earnings last quarter?
Currently, no data Available
Is Onconetix overvalued?
According to Wall Street analysts Onconetix’s price is currently Overvalued.
Does Onconetix pay dividends?
Onconetix does not currently pay dividends.
What is Onconetix’s EPS estimate?
Onconetix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Onconetix have?
Onconetix has 1,555,015 shares outstanding.
What happened to Onconetix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Onconetix?
Currently, no hedge funds are holding shares in ONCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Onconetix
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.